Apellis Provides Update on Ongoing Regulatory Review of Pegcetacoplan for GA in the European Union

<p>Conference call today at 8:30 a.m. ET WALTHAM, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) announced today an update on the ongoing review of its marketing authorization application (MAA) for intravitreal pegcetacoplan for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD) by the Committee for Medicinal […]</p>
<p>The post <a href="https://forextv.com/top-news/apellis-provides-update-on-ongoing-regulatory-review-of-pegcetacoplan-for-ga-in-the-european-union/">Apellis Provides Update on Ongoing Regulatory Review of Pegcetacoplan for GA in the European Union</a> appeared first on <a href="https://forextv.com">ForexTV</a>.</p>